Intra-articular botulinum toxin A for base-of-thumb osteoarthritis: protocol for a randomised trial (RHIBOT)

Charlotte Gil, Hendy Abdoul, Raphaël Campagna, Henri Guerini, Estelle Ieong, Franck Chagny, Catherine Bedin, Alexandra Roren, Marie-Martine Lefèvre-Colau, Serge Poiraudeau, Antoine Feydy, François Rannou, Christelle Nguyen, Charlotte Gil, Hendy Abdoul, Raphaël Campagna, Henri Guerini, Estelle Ieong, Franck Chagny, Catherine Bedin, Alexandra Roren, Marie-Martine Lefèvre-Colau, Serge Poiraudeau, Antoine Feydy, François Rannou, Christelle Nguyen

Abstract

Introduction: Recent studies have suggested that intra-articular injection of botulinum toxin A (BTA) may have analgesic effects in degenerative joint diseases. We aim to assess the efficacy of intra-articular injection of BTA associated with splinting in patients with trapeziometacarpal osteoarthritis (TMC OA).

Methods and analysis: We will conduct a randomised double-blind controlled trial. Overall, 60 individuals with TMC OA fulfilling adapted 1990 American College of Rheumatology criteria for hand OA will be recruited in one tertiary care centre in France and randomised to receive splinting + a single ultrasound-guided injection in the TMC joint of 50 Allergan Units of BTA resuspended in 1 mL saline or splinting +1 mL saline. Randomisation will be centralised. The allocation ratio will be 1:1. The primary outcome will be the mean change from baseline in base-of-thumb pain on a self-administered 11-point Numeric Rating Scale in 10-point increments at 3 months after injection. Secondary outcomes will be the mean change in base-of-thumb pain at 1 and 6 months, mean change in hand-specific activity limitations assessed by the self-administered Cochin Hand Function Scale, proportion of responders assessed by the Osteoarthritis Research Society International -Outcome Measures in Rheumatology (OMERACT) criteria and consumption of analgesics and non-steroidal anti-inflammatory drugs assessed by a self-administered 4-class scale at 3 and 6 months. Cointerventions will be allowed in both groups and will be self-reported. Adverse events will be recorded at 3 and 6 months. Participants, care providers and statisticians will be blinded to the allocated treatment.

Ethics and dissemination: The RHIBOT trial has been authorised by the Agence Nationale de Sécurité du Médicament and approved by the Comité de Protection des Personnes de Tours Ouest-1. The findings of the study will be disseminated in peer-reviewed journals and at conferences. If the results are positive, intra-articular BTA could be an efficient and safe complementary therapeutic option for patients with TMC OA.

Date and version identifier of the protocol: 8 January 2018, V. 2.0.

Trial registration number: NCT03187626; Pre-results.

Keywords: botulinum toxin A; intra-articular treatment; randomised trial; trapeziometacarpal osteoarthritis.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. Poole JU, Pellegrini VD. Arthritis of the thumb basal joint complex. J Hand Ther 2000;13:91–107. 10.1016/S0894-1130(00)80034-4
    1. Rannou F, Dimet J, Boutron I, et al. . Splint for base-of-thumb osteoarthritis: a randomized trial. Ann Intern Med 2009;150:661–9.
    1. Spaans AJ, van Minnen LP, Kon M, et al. . Conservative treatment of thumb base osteoarthritis: a systematic review. J Hand Surg Am 2015;40:16–21. 10.1016/j.jhsa.2014.08.047
    1. Bertozzi L, Valdes K, Vanti C, et al. . Investigation of the effect of conservative interventions in thumb carpometacarpal osteoarthritis: systematic review and meta-analysis. Disabil Rehabil 2015;37:2025–43. 10.3109/09638288.2014.996299
    1. Zhang W, Doherty M, Leeb BF, et al. . EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377–88. 10.1136/ard.2006.062091
    1. Hochberg MC, Altman RD, April KT, et al. . American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465–74. 10.1002/acr.21596
    1. Hadley HS, Wheeler JL, Petersen SW. Effects of intra-articular botulinum toxin type A (Botox) in dogs with chronic osteoarthritis. Vet Comp Orthop Traumatol 2010;23:254–8. 10.3415/VCOT-09-07-0076
    1. Heikkilä HM, Hielm-Björkman AK, Morelius M, et al. . Intra-articular botulinum toxin A for the treatment of osteoarthritic joint pain in dogs: a randomized, double-blinded, placebo-controlled clinical trial. Vet J 2014;200:162–9. 10.1016/j.tvjl.2014.01.020
    1. DePuy T, Howard R, Keegan K, et al. . Effects of intra-articular botulinum toxin type A in an equine model of acute synovitis: a pilot study. Am J Phys Med Rehabil 2007;86:777–83. 10.1097/PHM.0b013e3181157718
    1. Anderson S, Krug H, Dorman C, et al. . Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain. J Pain Res 2010;3:161–8. 10.2147/JPR.S12520
    1. Mahowald ML, Krug HE, Singh JA, et al. . Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain. Toxicon 2009;54:658–67. 10.1016/j.toxicon.2009.03.028
    1. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol 2013;9:654–64. 10.1038/nrrheum.2013.138
    1. Perrot S. Osteoarthritis pain. Best Pract Res Clin Rheumatol 2015;29:90–7. 10.1016/j.berh.2015.04.017
    1. Schaible HG. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep 2012;14:549–56. 10.1007/s11926-012-0279-x
    1. Nguyen C, Lefèvre-Colau MM, Poiraudeau S, et al. . Evidence and recommendations for use of intra-articular injections for knee osteoarthritis. Ann Phys Rehabil Med 2016;59:184–9. 10.1016/j.rehab.2016.02.008
    1. Singh JA. Use of botulinum toxin in musculoskeletal pain. F1000Res 2013;2:52 10.12688/f1000research.2-52.v2
    1. Nguyen C, Rannou F. The safety of intra-articular injections for the treatment of knee osteoarthritis: a critical narrative review. Expert Opin Drug Saf 2017;16:897–902. 10.1080/14740338.2017.1344211
    1. Boutron I, Altman DG, Moher D, et al. . CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. Ann Intern Med 2017;167:40–7. 10.7326/M17-0046
    1. Hoffmann TC, Glasziou PP, Boutron I, et al. . Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687 10.1136/bmj.g1687
    1. Altman R, Alarcón G, Appelrouth D, et al. . The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601–10. 10.1002/art.1780331101
    1. Keen HI, Lavie F, Wakefield RJ, et al. . The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis. Ann Rheum Dis 2008;67:651–5. 10.1136/ard.2007.077081
    1. Qvistgaard E, Kristoffersen H, Terslev L, et al. . Guidance by ultrasound of intra-articular injections in the knee and hip joints. Osteoarthritis Cartilage 2001;9:512–7. 10.1053/joca.2001.0433
    1. Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J Behav Ther Exp Psychiatry 1972;3:257–60. 10.1016/0005-7916(72)90045-6
    1. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry 2000;31:73–86. 10.1016/S0005-7916(00)00012-4
    1. Bolvig J, Juhl CB, Boutron I, et al. . Some Cochrane risk-of-bias items are not important in osteoarthritis trials: a meta-epidemiological study based on Cochrane reviews. J Clin Epidemiol 2018;95 10.1016/j.jclinepi.2017.11.026
    1. Trellu S, Dadoun S, Berenbaum F, et al. . Intra-articular injections in thumb osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Joint Bone Spine 2015;82:315–9. 10.1016/j.jbspin.2015.02.002
    1. McAlindon TE, Driban JB, Henrotin Y, et al. . OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthritis Cartilage 2015;23:747–60. 10.1016/j.joca.2015.03.005
    1. Reginster JL, Arden NK, Haugen IK, et al. . Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 2017. 10.1016/j.semarthrit.2017.12.003
    1. Duruöz MT, Poiraudeau S, Fermanian J, et al. . Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol 1996;23:1167–72.
    1. Poiraudeau S, Chevalier X, Conrozier T, et al. . Reliability, validity, and sensitivity to change of the Cochin hand functional disability scale in hand osteoarthritis. Osteoarthritis Cartilage 2001;9:570–7. 10.1053/joca.2001.0422
    1. Pham T, van der Heijde D, Altman RD, et al. . OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389–99. 10.1016/j.joca.2004.02.001
    1. . Standardised case causality assessment, 2012.
    1. Tubach F, Ravaud P, Martin-Mola E, et al. . Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res 2012;64:1699–707. 10.1002/acr.21747
    1. Kapandji A. [Clinical test of apposition and counter-apposition of the thumb]. Ann Chir Main 1986;5:67–73.
    1. Lefevre-Colau MM, Poiraudeau S, Oberlin C, et al. . Reliability, validity, and responsiveness of the modified Kapandji index for assessment of functional mobility of the rheumatoid hand. Arch Phys Med Rehabil 2003;84:1032–8.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner